Tradestie Institutional Equity Comparison Engine

MRNA vs BEAM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus BEAM at N/M Forward P/E and -267.7% operating margin (-96.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against BEAM sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs BEAM N/M Fwd P/E
Growth & Margin Winner MRNA
Op Margin -80.8% vs -267.7% ยท YoY +29.2% vs -96.8%
Momentum & Technical Winner MRNA
1Y +706.5% vs -0.4% ยท 52W Pos 67% vs 4%
Options & Structure Winner MRNA
CONSOLIDATION (52nd %ile IV) vs BREAKDOWN (34th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
BEAM NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.90
-0.19% 1D
Market Cap $2.2B
1M Return -14.9%
1Y Return -0.38%
Forward P/E N/M
Unified AI Score
60.3 / 100 BUY
Tech 70.0 Fund 66.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% BEAM -0.38% Spread: +706.83 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue BEAM Revenue MRNA Op. Margin BEAM Op. Margin Margin Edge
FY2018 $140M N/A -306.0% N/A MRNA
FY2019 $60M $0M -906.8% -417522.2% MRNA
FY2020 $800M $0M -95.0% -553166.7% MRNA
FY2021 $18.5B $50M 72.0% -757.0% MRNA
FY2022 $19.3B $60M 48.9% -555.6% MRNA
FY2023 $6.85B $380M -61.9% -46.7% BEAM
FY2024 $3.24B $60M -121.9% -654.3% MRNA
FY2025 $1.94B $140M -158.1% -274.6% MRNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (7) vs BEAM (3)
Institutional Metric MRNA BEAM Criterion Row Winner
Market Capitalization Scale $80.7B $2.2B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% -96.8% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% -267.7% Higher Margin MRNA
Net Profit Margin Profitability -110.5% -73.9% Higher Margin BEAM
Return on Equity (ROE) Capital Efficiency -34.5% -11.3% Higher ROE BEAM
52-Week Range Position Momentum 67% ($22โ€“$281) 4% ($20โ€“$38) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 2.09ฮฒ ยท 86% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 60.3 / 100 (BUY) Higher Composite BEAM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs BEAM Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BEAM BREAKDOWN
107d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live BEAM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor BEAM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.